Transcode Therapeutics, Inc. RNAZ
Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026
Transcode Therapeutics, Inc. (RNAZ) is a healthcare company listed in the US with a market value of about $22M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -356%.
About Transcode Therapeutics
Transcode Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. It was profitable in 0 of the last 6 years in our data. Its share count rose by 3978971% over three years (dilution for shareholders).
Score: 0.8 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net income | -$35M | -$17M | -$19M | -$18M | -$7M | -$2M |
| Free cash flow | -$20M | -$13M | -$18M | -$16M | -$6M | — |
| EPS (diluted) | $-52.59 | $-1336.63 | $-96954.99 | $-1013355.74 | $-606429.69 | $-381826.10 |
| Net margin | — | — | — | — | — | — |
| ROIC | -213.9% | — | -733.5% | -454.3% | -23.8% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Transcode Therapeutics pay a dividend?
Not currently.
Is Transcode Therapeutics a good stock to buy?
We do not give buy or sell advice. Transcode Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.